Secondary Outcomes From the Child/Adolescent Anxiety Multimodal Study: Implications for Clinical Practice

Combination treatment (CBT + sertraline) was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -15.7, t= -6.4 (MASC-P); b= -9.8, t= -5.9 (SCARED)

Sertraline monotherapy was superior to placebo at week 12 on parent-reported youth anxiety symptoms across both the MASC-P and Parent SCARED measures.

Effect: improvement; b= -11.1, t= -4.4 (MASC-P); b= -7.9, t= -4.7 (SCARED)

CBT showed mixed results compared to placebo at week 12 on parent-reported anxiety: superior on the MASC-P but not statistically different from placebo on the Parent SCARED.

Effect: mixed; b= -7.0, t= -2.9 (MASC-P, superior to PBO); adj p=.26 (SCARED, not superior to PBO)

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Youth self-reports revealed minimal between-group differences across treatment conditions, with only one significant finding: sertraline was associated with lower week 12 anxiety than placebo on the Y

Effect: null; b= -4.68, t= -2.80 (only significant comparison: SRT vs PBO on Youth MASC week 12)

By week 36, parent reports of many youth outcomes were comparable across the three active treatment conditions, with the acute superiority of medication treatments over CBT not enduring across the mai

Effect: null